Circulating Metabolites Associated with Alcohol Intake in the European Prospective Investigation into Cancer and Nutrition Cohort. by van Roekel, Eline H et al.
nutrients
Article
Circulating Metabolites Associated with Alcohol
Intake in the European Prospective Investigation into
Cancer and Nutrition Cohort
Eline H. van Roekel 1, Laura Trijsburg 2, Nada Assi 2, Marion Carayol 3,4 ID , David Achaintre 5,
Neil Murphy 6, Sabina Rinaldi 5, Julie A. Schmidt 7 ID , Magdalena Stepien 6, Rudolf Kaaks 8,
Tilman Kühn 8, Heiner Boeing 9, Khalid Iqbal 9 ID , Domenico Palli 10, Vittorio Krogh 11,
Rosario Tumino 12, Fulvio Ricceri 13,14 ID , Salvatore Panico 15, Petra H. Peeters 16,
Bas Bueno-de-Mesquita 17,18,19,20, Eva Ardanaz 21,22,23, Leila Lujan-Barroso 24, J. Ramón Quirós 25,
José M. Huerta 23,26 ID , Elena Molina-Portillo 23,27, Miren Dorronsoro 28,
Konstantinos K. Tsilidis 29,30 ID , Elio Riboli 29, Agnetha Linn Rostgaard-Hansen 31,
Anne Tjønneland 31 ID , Kim Overvad 32,33, Elisabete Weiderpass 34,35,36,37,
Marie-Christine Boutron-Ruault 38,39, Gianluca Severi 38,39,40, Antonia Trichopoulou 41,42,
Anna Karakatsani 41,43, Anastasia Kotanidou 41,44, Anders Håkansson 45 ID , Johan Malm 46,
Matty P. Weijenberg 1 ID , Marc J. Gunter 6, Mazda Jenab 6, Mattias Johansson 47, Ruth C. Travis 7,
Augustin Scalbert 5 and Pietro Ferrari 2,*
1 Department of Epidemiology, GROW School for Oncology and Developmental Biology,
Maastricht University, 6229 HA Maastricht, The Netherlands;
eline.vanroekel@maastrichtuniversity.nl (E.H.v.R.); mp.weijenberg@maastrichtuniversity.nl (M.P.W.)
2 Nutritional Methodology and Biostatistics Group, Nutrition and Metabolism Section, International Agency
for Research on Cancer (IARC-WHO), 69372 Lyon, France; laura.trijsburg@wur.nl (L.T.);
assin@students.iarc.fr (N.A.)
3 Epidaure, Prevention Department of the Institut régional du Cancer de Montpellier (ICM),
34298 Montpellier, France; Marion.Carayol@icm.unicancer.fr
4 Laboratoire Epsylon, Paul Valery University of Montpellier, 34090 Montpellier, France
5 Biomarkers Group, Nutrition and Metabolism Section, International Agency for Research on
Cancer (IARC-WHO), 69372 Lyon, France; achaintred@iarc.fr (D.A.); rinaldis@iarc.fr (S.R.);
ScalbertA@iarc.fr (A.S.)
6 Nutritional Epidemiology Group, Nutrition and Metabolism Section, International Agency for Research on
Cancer (IARC-WHO), 69372 Lyon, France; MurphyN@iarc.fr (N.M.); StepienM@iarc.fr (M.S.);
GunterM@iarc.fr (M.J.G.); jenabm@iarc.fr (M.J.)
7 Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford,
Oxford OX3 7LF, UK; julie.schmidt@ndph.ox.ac.uk (J.A.S.); ruth.travis@ndph.ox.ac.uk (R.C.T.)
8 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany;
r.kaaks@dkfz-heidelberg.de (R.K.); t.kuehn@Dkfz-Heidelberg.de (T.K.)
9 Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke,
14558 Nuthetal, Germany; boeing@dife.de (H.B.); khalid.iqbal@dife.de (K.I.)
10 Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute—ISPO,
50141 Florence, Italy; d.palli@ispo.toscana.it
11 Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy;
Vittorio.Krogh@istitutotumori.mi.it
12 Cancer Registry and Histopathology Department, Civic—M.P.Arezzo Hospital, ASP, 97100 Ragusa, Italy;
rtumino@tin.it
13 Department of Clinical and Biological Sciences, University of Turin, 10124 Turin, Italy; fulvio.ricceri@unito.it
14 Unit of Epidemiology, Regional Health Service ASL TO3, 10095 Turin, Italy
15 Dipartimento di Medicina Clinica e Chirurgia, Federico II University, 80138 Naples, Italy; spanico@unina.it
16 Department of Epidemiology, Julius Center for Health Sciences and Primary Care,
University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands;
P.H.M.Peeters@umcutrecht.nl
Nutrients 2018, 10, 654; doi:10.3390/nu10050654 www.mdpi.com/journal/nutrients
Nutrients 2018, 10, 654 2 of 18
17 Former Senior Scientist, Dept. for Determinants of Chronic Diseases (DCD), National Institute for Public
Health and the Environment (RIVM), 3721 MA Bilthoven, The Netherlands;
basbuenodemesquita@gmail.com
18 Former Associate Professor, Department of Gastroenterology and Hepatology,
University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
19 Visiting Professor, Dept. of Epidemiology and Biostatistics, The School of Public Health, Imperial College,
London SW7 2AZ, UK
20 Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya,
Kuala Lumpur 50603, Malaysia
21 Navarra Public Health Institute, 31003 Pamplona, Spain; me.ardanaz.aicua@cfnavarra.es
22 IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain
23 CIBER de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain;
jmhuerta.carm@gmail.com (J.M.H.); elena.molina.easp@juntadeandalucia.es (E.M.-P.)
24 Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of
Oncology-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain; llujan@iconcologia.net
25 Public Health Directorate, 33005 Oviedo, Spain; epic_asturias@asturias.org
26 Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, 30008 Murcia, Spain
27 Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs, GRANADA,
Hospitales Universitarios de Granada/Universidad de Granada, 18010 Granada, Spain
28 Basque Regional Health Department, Public Health Direction and Biodonostia Research Institute CIBERESP,
20014 Donostia, Spain; m-dorronsoro@euskadi.eus
29 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London,
London SW7 2AZ, UK; ktsilidis@gmail.com (K.K.T.); e.riboli@imperial.ac.uk (E.R.)
30 Department of Hygiene and Epidemiology, University of Ioannina School of Medicine,
45110 Ioannina, Greece
31 Danish Cancer Society Research Center, 2100 Copenhagen, Denmark; agnrha@cancer.dk (A.L.R.-H.);
annet@CANCER.DK (A.T.)
32 Department of Public Health, Section for Epidemiology, Aarhus University, 8000 Aarhus, Denmark;
ko@ph.au.dk
33 Department of Cardiology, Aalborg University Hospital, 9100 Aalborg, Denmark
34 Department of Community Medicine, Faculty of Health Sciences, University of Tromsø,
The Arctic University of Norway, 9019 Tromsø, Norway; Elisabete.Weiderpass.Vainio@ki.se
35 Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research,
NO-0304 Oslo, Norway
36 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden
37 Genetic Epidemiology Group, Folkhälsan Research Center, 00290 Helsinki, Finland
38 CESP “Health across Generations”, INSERM, Univ Paris-Sud, UVSQ, Univ Paris-Saclay, 94800 Villejuif,
France; marie-christine.boutron@gustaveroussy.fr (M.-C.B.-R.); gianluca.severi@gustaveroussy.fr (G.S.)
39 Gustave Roussy, 94800 Villejuif, France
40 Cancer Epidemiology Centre, Cancer Council Victoria and Centre for Epidemiology and Biostatistics,
Melbourne School of Population and Global Health, The University of Melbourne,
Melbourne, VIC 3010, Australia
41 Hellenic Health Foundation, 115 27 Athens, Greece; atrichopoulou@hhf-greece.gr (A.T.);
a.karakatsani@hhf-greece.gr (A.Ka.); akotanid@gmail.com (A.Ko.)
42 WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in
Public Health, Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine,
National and Kapodistrian University of Athens, 157 72 Athens, Greece
43 2nd Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens,
“ATTIKON” University Hospital, 124 62 Haidari, Greece
44 1st Department of Critical Care Medicine & Pulmonary Services, University of Athens Medical School,
Evangelismos Hospital, 10675 Athens, Greece
45 Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Psychiatry,
SE-221 00 Lund, Sweden; anders_c.hakansson@med.lu.se
46 Department of Translational Medicine, Clinical Chemistry, Lund University, Skåne University Hospital,
205 02 Malmö, Sweden; johan.malm@med.lu.se
Nutrients 2018, 10, 654 3 of 18
47 Genetic Epidemiology Group, Section of Genetics, International Agency for Research on
Cancer (IARC-WHO), 69372 Lyon, France; johanssonm@iarc.fr
* Correspondence: FerrariP@iarc.fr; Tel.: +33-472-738-031
Received: 26 February 2018; Accepted: 17 May 2018; Published: 22 May 2018


Abstract: Identifying the metabolites associated with alcohol consumption may provide insights
into the metabolic pathways through which alcohol may affect human health. We studied
associations of alcohol consumption with circulating concentrations of 123 metabolites among
2974 healthy participants from the European Prospective Investigation into Cancer and
Nutrition (EPIC) study. Alcohol consumption at recruitment was self-reported through dietary
questionnaires. Metabolite concentrations were measured by tandem mass spectrometry (BIOCRATES
AbsoluteIDQTM p180 kit). Data were randomly divided into discovery (2/3) and replication (1/3) sets.
Multivariable linear regression models were used to evaluate confounder-adjusted associations of
alcohol consumption with metabolite concentrations. Metabolites significantly related to alcohol intake
in the discovery set (FDR q-value < 0.05) were further tested in the replication set (Bonferroni-corrected
p-value < 0.05). Of the 72 metabolites significantly related to alcohol intake in the discovery set, 34 were
also significant in the replication analysis, including three acylcarnitines, the amino acid citrulline,
four lysophosphatidylcholines, 13 diacylphosphatidylcholines, seven acyl-alkylphosphatidylcholines,
and six sphingomyelins. Our results confirmed earlier findings that alcohol consumption was
associated with several lipid metabolites, and possibly also with specific acylcarnitines and amino
acids. This provides further leads for future research studies aiming at elucidating the mechanisms
underlying the effects of alcohol in relation to morbid conditions.
Keywords: alcohol; targeted metabolomics; lipid metabolites; amino acids; acylcarnitines
1. Introduction
The harmful use of alcohol is among the main modifiable risk factors for human morbidity,
disability, and mortality worldwide [1]. It has been associated with over 200 health conditions including
neuropsychiatric conditions, liver cirrhosis, several cancers, hypertensive heart disease, fetal alcohol
syndrome, and infectious diseases [1]. Moderate alcohol intake was found to be inversely associated
with the risk of type 2 diabetes [2] and heterogeneous associations were observed for cardiovascular
disease subtypes, with an inverse association with coronary heart disease, and a positive association
with stroke [3,4]. Each year, alcohol causes approximately 3.3 million deaths, i.e., one in every 20 deaths
in the world [1]. A better understanding of metabolic pathways affected by alcohol consumption may
contribute to the development of mechanism-tailored intervention strategies to prevent and treat
alcohol-related conditions (e.g., through identification of pharmacotherapy targets). Furthermore,
it may help to identify biomarkers of alcohol consumption facilitating early preventive strategies in
individuals at risk of developing alcohol-related morbidities.
Metabolomics is the measurement of the dynamic metabolic responses of a living system to
pathophysiological and other stimuli, through a comprehensive characterization of molecules of
endogenous and exogenous origin in biological samples [5]. Applying high-throughput metabolomics
approaches in population-based studies can be used to examine how environmental factors, such as
alcohol consumption, are associated with human metabolism [6,7]. Targeted metabolomics approaches
focus on measuring concentrations of predefined panels of metabolites involved in certain biochemical
pathways of the human body [8]. This enables the identification of metabolites within those panels
that are associated with alcohol consumption, possibly providing insight into the metabolic pathways
through which alcohol may exert adverse health effects.
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To our knowledge, three previous population-based studies have investigated associations of
total alcohol intake [9,10] and/or consumption of specific alcoholic beverages [11] with circulating
concentrations of a panel of metabolites using a targeted metabolomics approach (BIOCRATES
AbsoluteIDQTM p150 kit). These studies were conducted in German populations (n = 2090 [9] and
n = 1030 [10]), and in over 3500 female twins from the United Kingdom [11], and mainly observed
associations of self-reported alcohol intake with phospholipid and sphingolipid metabolism. Two of
these studies partly replicated their findings in similar cohorts [9,11]. However, no study has yet
investigated these associations in other European populations, and potential sex-specific associations
remain unclear [9,10]. Furthermore, no study to date has examined how these associations may be
influenced by smoking habits. This is relevant since smoking may interact with alcohol in its effect on
the risk of diseases such as cancer [12–14].
Our objective was to further investigate associations of alcohol consumption with circulating
concentrations of metabolites using a large dataset of ~3000 participants of the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort, including participants from 10 European
countries. We applied a discovery and replication approach, and explored potential heterogeneity by
sex and smoking status.
2. Materials and Methods
2.1. Study Design and Participants
EPIC is a large multicenter cohort study; its design and methods have been described in
detail previously [15,16]. Between 1992 and 2000, approximately 520,000 healthy men and women
(mostly 35–70 years of age) were recruited in 23 centers throughout 10 European countries [16].
There is no detailed information available on ethnicity of EPIC subjects. However, based on the
ethnic composition of the regions involved in the study at the time of recruitment, the vast majority
(>97%) of participants recruited to the EPIC cohort are of Caucasian origin. At recruitment, dietary
and lifestyle data were obtained using questionnaires. In addition, blood samples were collected from
most participants by each center in a standardized manner [16]. Blood samples were stored at the
International Agency for Research on Cancer (IARC, Lyon, France) at −196 ◦C in liquid nitrogen.
The EPIC study was approved by the relevant ethical review committees of each center and by the
IARC ethics committee. All study participants provided informed consent. For information on how
to submit an application for gaining access to EPIC data and/or biospecimens, please follow the
instructions at http://epic.iarc.fr/access/index.php.
This study used data from 2974 control participants from four case-control studies on colorectal
(n = 491) [17], hepatobiliary (n = 327) [18], kidney (n = 635) [19], and prostate cancer (n = 1521) [20]
nested in the EPIC cohort, for which targeted metabolomics data had been acquired. None of the control
participants were included in multiple case-control studies (i.e., no duplicates). Figure S1 depicts
the flow chart of participant inclusion. These case-control studies will hereafter be referred to as
‘sub-studies’. In the colorectal cancer case-control study, mainly individuals with fasting blood samples
(≥6 h) were included. In the hepatobiliary cancer case-control study, individuals from Denmark and
Sweden were included, but not in the other sub-studies since blood storage of participants from these
countries was not centralized at IARC. For all sub-studies, controls were mostly selected from the full
cohort of individuals who were alive and free of cancer (except non-melanoma skin cancer) at the time
of diagnosis of the cases, using incidence density sampling and with controls matched to cases by
age, sex, study center, follow-up time since blood collection, time of day and fasting status at time of
blood collection (<3, 3–6, >6 h). For women, additional matching criteria included menopausal status
(premenopausal, postmenopausal, perimenopausal/unknown; this criterion was not applied in the
kidney cancer case-control study), phase of menstrual cycle, and hormone replacement therapy use
at blood collection. Only control participants were included in this study to avoid any potential bias
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due to metabolic changes induced by pre-clinical cancer development at the time of recruitment in
participants that were subsequently diagnosed with cancer (i.e., cases).
2.2. Alcohol Intake and Other Lifestyle Variables
Dietary intake including alcohol consumption was assessed at baseline using validated
country-specific or center-specific questionnaires designed to measure dietary consumption in the year
preceding its administration. Alcohol consumption at recruitment was calculated in grams per day
(g/day) as previously described [21]. Briefly, the frequency of intake of glasses of alcoholic beverages,
including wine, fortified wines, beer and cider, spirits and brandy, aniseed drinks and liqueurs,
as reported in the questionnaire were converted into g/day of alcohol by applying empirically derived
definitions of standard drinks for each beverage and country in EPIC, and summed up to determine
intakes of alcohol subtypes. These were further summed up to calculate total alcohol intake through
alcoholic beverages. Participants were classified according to their alcohol intake as non-drinkers
(<0.1 g/day), light drinkers (0.1–4.9 g/day), moderate drinkers (5.0–39.9 g/day), or heavy drinkers
(≥40 g/day).
Other dietary and lifestyle variables were considered in the study. Smoking status and physical
activity were assessed through the EPIC lifestyle questionnaire [22]. The Cambridge physical activity
index was used, which combines information on occupational activities with recreational activities [23].
Body mass index (BMI; kg/m2) was computed from height and weight, measured by trained personnel
according to standardized protocols in all centers, except for the majority of the French and Oxford
cohorts, where height and weight were self-reported [24].
2.3. Alcohol Intake and Other Lifestyle Variables
A targeted metabolomics approach was applied to measure the concentrations of a panel of
metabolites in blood (serum for hepatobiliary cancer study, and citrate plasma for all other sub-studies;
after two or three freeze–thaw cycles in all cases) at IARC’s laboratory, Lyon, France, using the
Absolute IDQTM p180 kit (BIOCRATES Life Sciences AG, Innsbruck, Austria). The assay quantifies
up to 186 metabolites, namely acylcarnitines, amino acids, biogenic amines, a sum of hexoses,
phosphatidylcholines (PCs) including lysoPCs, diacyl PCs, and acyl–alkyl PCs, and sphingomyelins
(SMs). The procedures and metabolite nomenclature have been described in detail previously [25,26].
Briefly, samples were analyzed by ultra-performance liquid chromatography (LC; 1290 Series HPLC;
Agilent, Les Ulis, France) coupled to a tandem mass spectrometer (MS/MS; QTrap 5500; AB Sciex,
Les Ulis, France, for the hepatobiliary and kidney cancer sub-studies; and Triple Quad 4500; AB Sciex,
Framingham, MA, USA, for the colorectal and prostate cancer sub-studies). Amino acids and biogenic
amines were quantified by an LC-MS/MS method using appropriately labeled internal standards,
whereas flow injection analysis was used for acylcarnitines, hexoses, PCs, and SMs. The samples were
analyzed at different time points in each sub-study. In total, there were 89 analytical batches with
about 30–39 samples from control participants per batch.
Metabolites with inter-batch or intra-batch coefficients of variation (CVs) > 20% for analytical
replicates were excluded from the analysis in all sub-studies, leading to a total of 158 metabolites
being detected in the controls of at least one of the sub-studies. Of these, metabolites with >20%
of missing values and/or measurements outside the measurable range (i.e., below the limit of
detection/quantification or above highest calibration standards) were excluded, resulting in a total
of 123 metabolites included in the current analysis, including 10 acylcarnitines, 21 amino acids,
four biogenic amines, 75 PCs (eight lysoPCs, 33 diacylPCs, and 34 acyl-alkylPCs), 12 SMs, and a sum
of hexoses (Table S1 lists measurement information on all measured metabolites). For the included
metabolites, measurements below the limit of detection or quantification (where applicable) were set
to half the batch-specific limit of detection or quantification, respectively. For the first assay round
of the prostate cancer sub-study (batches 1–31), no limits of detection/quantification were available
so these were set to half the lowest measured concentration in that batch. Finally, all measurements
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above the highest calibration standards were set to the highest standard. Metabolite concentrations
(µM) were log-transformed (natural logarithm) as this better approximated a normal distribution for
most metabolites, and Z-standardized for better comparison of metabolites with different averages
and standard deviations (SDs) of blood concentrations.
A good to excellent reliability for the majority of compounds measured through this method was
observed when comparing samples collected in the same individuals over a period of four months [27]
and two years [25] (intra-class correlation coefficients > 0.50 for most metabolites).
2.4. Statistical Analysis
Descriptive analyses were performed for sociodemographic, lifestyle, and blood sampling-related
variables. Summary statistics and Spearman correlation coefficients were computed for metabolites
and visualized in heat maps.
The Principal Component Partial R-square (PC-PR2) method [28] was applied to estimate the
contribution to total variability in metabolite concentrations attributed to self-reported alcohol intake
(natural logarithm of continuous alcohol intake + 1) and other factors, including sub-study (categorical),
batch (categorical), sex (categorical), age at blood collection (continuous), country (categorical),
fasting status at blood collection (categorical: <3 h/3–6 h/>6 h/unknown), smoking status at
recruitment (categorical: current/former/never/unknown), BMI (continuous), Cambridge physical
activity index (categorical: inactive/moderately inactive/moderately active/active/unknown),
and daily intake of energy, meat and meat products, fish and shellfish (all continuous). Firstly, principal
component analysis was conducted on metabolite concentrations, and the components explaining
> 80% of the total variability were retained (c = 18). Then, in multiple linear models the component
scores were, in turn, regressed on the list of aforementioned independent variables, and Rpartial2 for
each covariate was estimated separately for each component. Lastly, an overall Rpartial2 for each
covariate was calculated as a weighted average, using the eigenvalues of each principal component c
as weights. As a result, the Rpartial2 provides a measure of the variability in the ensemble of metabolite
concentrations that each covariate contributes to explain [28].
To be able to adjust for sex, sub-study, and analytical batch in the main analysis, residuals of each
of the Z-standardized ln-transformed metabolite concentrations were computed from linear mixed
models with sex as an independent variable and random intercepts for analytical batches nested
within studies. The residuals were used as dependent variables in linear regression models testing
confounder-adjusted associations with alcohol intake.
The dataset was randomly split into discovery (2/3 of all participants) and replication sets
(1/3). Associations of alcohol intake with metabolites were analyzed in the discovery set using
multiple linear regression, with false discovery rate (FDR) adjustment of p-values, using the
Benjamini–Hochberg method (q-values < 0.05 were considered significant) [29,30]. Alcohol intake
(g/day) was log-transformed (natural logarithm of continuous alcohol intake + 1), to make
regression residuals more homoscedastic. Models were adjusted for sex, age at blood collection
(continuous), country, fasting status at blood collection (<3 h/3–6 h/>6 h/unknown), smoking status
at recruitment (current/former/never/unknown), BMI (continuous), Cambridge physical activity
index (inactive/moderately inactive/moderately active/active/unknown), and daily intake of energy,
meat and meat products, fish and shellfish (all continuous). Statistically significant metabolites
were further evaluated in the replication set, using the same list of confounders as in the discovery
analysis. In this phase, the more conservative Bonferroni correction was used (Bonferroni-adjusted
p-values < 0.05 were considered significant) [31].
2.4.1. Heterogeneity by Sex and Smoking Status
To explore potential heterogeneity by sex and smoking status, interaction terms were tested with
FDR-adjustment. In addition, sex-stratified analyses were performed to evaluate potential sex-specific
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alcohol-related metabolites. In addition, analyses were conducted in non-smokers to rule out the
possibility of residual confounding by smoking.
2.4.2. Sensitivity Analyses
Linearity of associations was investigated using penalized spline regression models [32].
Smoothened scatterplots with five knots were generated and goodness-of-fit tests were performed [33].
In addition, analyses in the discovery and replication sets were conducted comparing heavy vs. light
drinking (≥40 and 0.1–4.9 g/day, respectively) to possibly identify metabolites associated with extreme
alcohol intake. Furthermore, an analysis stratified by sub-study was conducted to investigate the
consistency of findings across sub-studies for the metabolites detected as significant in the replication
dataset. Similar results were obtained in sensitivity analyses in the discovery set as in the main
analysis, including (1) addition of education level as a potential confounder; (2) excluding hepatobiliary
controls (serum samples vs. citrate plasma in other studies); (3) excluding non-drinkers, and therefore,
these results were not reported.
Linear regression analyses and penalized splines were conducted using Stata [34]. The PC-PR2
analysis, heat maps, and Manhattan plots were computed in R [35].
3. Results
3.1. Participant Characteristics
General characteristics of the study population (n = 2974, 75% men), within the discovery
(n = 1983) and replication sets (n = 991) are shown in Table 1. As expected, the two sets were similar
in terms of socio-demographic, lifestyle, and blood-sampling related characteristics, thus confirming
the random allocation of study participants. Mean age at recruitment was 58.3 years (SD = 7.7).
The majority of participants were overweight (BMI: 25.0–29.9 kg/m2; 49.7%) or obese (BMI > 30 kg/m2;
17.9%) at recruitment. Most participants were inactive (28.1%) or moderately inactive (33.4%),
whilst 21.1% were moderately active and 17.4% active. At baseline over one third of the population
reported being never (38.9%) and former smokers (38.5%), while 22.6% indicated that they were current
smokers. The median reported alcohol intake at recruitment was 13.7 g/day in men (5th, 95th percentile:
0.0, 64.0) and 2.8 g/day in women (0.0, 25.7). A total of 345 participants were classified as
non-drinkers (11.6%; 48.7% men), 726 as light drinkers (24.4%; 62.7% men), 1521 as moderate drinkers
(51.1%; 81.8% men), and 382 as heavy drinkers (12.8%; 95.3% men). Participant characteristics by
sub-study were compared in Table S2, indicating similar study populations overall.
Table 1. Socio-demographic, lifestyle, and blood-sampling related characteristics of participants
included in the total dataset and in the discovery and replication sets a.
Discovery Set (n = 1983, 66.7%) Replication Set (n = 991, 33.3%) Total Dataset (n = 2974, 100%)
Age, mean (SD) 58.5 (7.6) 58.0 (7.9) 58.3 (7.7)
Sex, n (%)
Men 1497 (75.5) 734 (74.1) 2231 (75.0)
Women 486 (24.5) 257 (25.9) 743 (25.0)
Education level, n (%) b
None/primary 891 (46.8) 408 (43.1) 1299 (45.5)
Secondary 236 (12.4) 117 (12.4) 353 (12.4)
Technical/professional 410 (21.5) 239 (25.2) 649 (22.8)
University or higher 369 (19.4) 183 (19.3) 552 (19.4)
Alcohol intake in men (g/day), median
(5th, 95th perc) 14.0 (0.0, 67.9) 14.0 (0.0, 67.9) 13.7 (0.0, 64.0)
Alcohol intake in women (g/day),
median (5th, 95th perc) 3.2 (0.0, 26.4) 2.2 (0.0, 25.7) 2.8 (0.0, 25.7)
Categories of alcohol intake, n (%)
Non-drinkers (<0.1 g/day) 227 (11.5) 118 (11.9) 345 (11.6)
Light drinkers (0.1–4.9 g/day) 485 (24.5) 241 (24.3) 726 (24.4)
Moderate drinkers (5–39.9 g/day) 1026 (51.7) 495 (50.0) 1521 (51.1)
Heavy drinkers (≥40 g/day) 245 (12.4) 137 (13.8) 382 (12.8)
Body mass index (kg/m2), mean (SD) 26.8 (3.8) 26.9 (3.6) 26.8 (3.7)
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Table 1. Cont.
Discovery Set (n = 1983, 66.7%) Replication Set (n = 991, 33.3%) Total Dataset (n = 2974, 100%)
Physical activity, n (%) c
Inactive 542 (27.7) 281 (28.7) 823 (28.1)
Moderately inactive 652 (33.4) 328 (33.5) 980 (33.4)
Moderately active 406 (20.8) 214 (21.9) 620 (21.1)
Active 354 (18.1) 156 (15.9) 510 (17.4)
Smoking status, n (%) d
Current smoker 445 (22.7) 219 (22.6) 664 (22.7)
Former smoker 764 (38.9) 365 (37.7) 1129 (38.5)
Never smoker 754 (38.4) 385 (39.7) 1139 (38.9)
Meat intake (g/day), median
(5th, 95th perc) 106.1 (34.1, 220.2) 108.4 (31.2, 233.0) 106.6 (32.9, 222.9)
Fish intake (g/day), median
(5th, 95th perc) 28.8 (2.5, 113.3) 28.8 (3.0, 113.0) 28.8 (2.5, 113.2)
Energy intake (kcal/day), median
(5th, 9th perc) 2187.4
(1330.0,
3480.4) 2190.5
(1304.9,
3451.3) 2188.3
(1327.7,
3480.4)
Fasting status, n (%) e
≥6 h 775 (40.2) 391 (40.4) 1166 (40.2)
3–5.9 h 371 (19.2) 193 (19.9) 564 (19.5)
<3 h 784 (40.6) 385 (39.7) 1169 (40.3)
Sub-study, n (%)
Colorectal cancer controls 334 (16.8) 157 (15.8) 491 (16.5)
Kidney cancer controls 401 (20.2) 234 (23.6) 635 (21.4)
Hepatobiliary cancer controls 209 (10.5) 118 (11.9) 327 (11.0)
Prostate cancer controls 1039 (52.4) 482 (48.6) 1521 (51.1)
Abbreviations: n, number; perc, percentile; SD, standard deviation. a The discovery and replication set were taken
as random samples without replacement of 66.7% and 33.3% of the total dataset, respectively. b Data missing for
121 participants (77 from discovery set (3.9%) and 44 from replication set (4.4%)). c Cambridge physical activity
index: cross-classification of the level of occupational activity with cycling and sports activities and recreational
activities [23]; data missing for 41 participants (29 from discovery set (1.5%) and 12 from replication set (1.2)).
d Data missing for 42 participants (20 from discovery set (1.0%) and 22 from replication set (2.2%)). e Data missing
for 75 participants (53 from discovery set (2.7) and 22 from replication set (2.2)).
3.2. Metabolome Characteristics and PC-PR2
The summary statistics of metabolite concentrations are reported in Table S3, and median
Spearman correlation coefficients among the 123 metabolites are shown in Figure S2. Within classes of
metabolites, median correlations among SMs and lysoPCs were 0.83 (5th, 95th percentile: 0.50, 0.92)
and 0.62 (0.44, 0.76), respectively, while lower values were found for acyl-alkyl PCs (0.43; 0.12, 0.74),
diacyl PCs (0.34;−0.10, 0.69), amino acids (0.31; 0.09, 0.62), acylcarnitines (0.28; 0.03, 0.61), and biogenic
amines (0.22; 0.11, 0.36).
Results of PC-PR2 analysis indicated that sub-study, lifestyle, and laboratory variables combined
explained 41.9% of the total variability in metabolite concentrations (Figure 1). The main contributors
to variability were sub-study (21.5%), country (5.8%), and batch (4.9%), while alcohol intake
explained 1.1%. Sex and smoking status explained 0.7% and 2.6% of the total variability, respectively.
Additional covariates such as education level, macronutrient intake (fat, carbohydrates and protein),
and time between blood collection and metabolomics assay showed marginal percentages of explained
variability in the PC-PR2 analysis and were not included in the final analysis.
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Figure 2. Manhattan plots showing −log10 of FDR q-values and Bonferroni-adjusted p-values
of associations of alcohol intake with metabolites in the (a) discovery (false discovery rate
method; n = 1983) and (b) replication analysis (Bonferroni correction; n = 991), respectively.
Footnote: Analyzed with multivariable linear regression analyses analyzing associations of alcohol
consumption (ln-transformed alcohol intake + 1) as main independent variable and as dependent
variables the residuals obtained from linear mixed models with Z-standardized ln-transformed
metabolite concentrations as dependent variables, sex as independent variable, and random intercepts
for analytical batches nested within studies. Adjusted for: sex; age (y; continuous), body mass index
(kg/m2; continuous), self-reported physical activity levels (Cambridge physical activity index [23]:
inactive, moderately inactive, moderately active, active, unknown), fasting status (≥6 h, 3–5.9 h, <3 h,
unknown), meat intake (g/day; continuous), fish intake (g/day; continuous), energy intake (kcal/day;
continuous), country, and smoking status (current, f rmer, never, unknown). The discovery and
replication set were taken as random samples without replacement of 66.7% and 33.3% of the t tal
dataset, respectively. Q-values/Bonferro i-adjusted p-values <1.0 × 10− (number of decimals above
reporting limits of STATA and thus not provided) were set to 1.0 × 10−12.
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Table 2. Results of discovery and replication analysis of metabolites that were significantly associated
with alcohol consumption in the discovery and replication set a.
Discovery Analysis (n = 1983) b Replication Analysis (n = 991) b
Metabolite β (SE) p-Value (FDR q-Value) c β (SE) p-Value (Bonf.-adj. p-Value) d
Acylcarnitine C14:1 0.05 (0.02) 2.2 × 10
−3
2.2 × 10−3 (4.7 × 10
−3) 0.08 (0.02) 6.5 × 10−4 (4.7 × 10−2)
Acylcarnitine C16 0.11 (0.02) <1.0 × 10−12 (<1.0 × 10−12) 0.13 (0.02) 4.4 × 10−9 (3.2 × 10−7)
Acylcarnitine C18:1 0.06 (0.02) 2.4 × 10−4 (6.2 × 10−4) 0.08 (0.02) 6.7 × 10−4 (4.8 × 10−2)
Citrulline −0.10 (0.02) 8.2 × 10−10 (5.9 × 10−9) −0.10 (0.02) 1.2 × 10−5 (8.9 × 10−4)
LysoPC a C16:0 0.09 (0.01) 1.8 × 10−10 (1.5 × 10−9) 0.08 (0.02) 6.4 × 10−5 (4.6 × 10−3)
LysoPC a C16:1 0.11 (0.02) <1.0 × 10−12 (<1.0 × 10−12) 0.12 (0.02) 2.5 × 10−8 (1.8 × 10−6)
LysoPC a C17:0 −0.09 (0.01) 1.0 × 10−10 (9.5 × 10−10) −0.11 (0.02) 2.0 × 10−7 (1.4 × 10−5)
LysoPC a C20:4 0.06 (0.02) 3.5 × 10−5 (1.2 × 10−4) 0.08 (0.02) 1.2 × 10−4 (8.5 × 10−3)
PC aa C30:0 0.10 (0.01) <1.0 × 10−12 (<1.0 × 10−12) 0.12 (0.02) 4.3 × 10−8 (3.1 × 10−6)
PC aa C32:0 0.12 (0.01) <1.0 × 10−12 (<1.0 × 10−12) 0.13 (0.02) 5.3 × 10−10 (3.8 × 10−8)
PC aa C32:1 0.20 (0.02) <1.0 × 10−12 (<1.0 × 10−12) 0.22 (0.02) <1.0 × 10−12 (<1.0 × 10−12)
PC aa C32:2 0.07 (0.02) 7.3 × 10−6 (3.0 × 10−5) 0.10 (0.02) 1.6 × 10−5 (1.2 × 10−3)
PC aa C32:3 −0.04 (0.01) 2.7 × 10−3 (5.8 × 10−3) −0.08 (0.02) 4.8 × 10−5 (3.5 × 10−3)
PC aa C34:1 0.17 (0.01) <1.0 × 10−12 (<1.0 × 10−12) 0.14 (0.02) 2.0 × 10−11 (1.4 × 10−9)
PC aa C34:3 0.07 (0.01) 4.0 × 10−7 (2.1 × 10−6) 0.08 (0.02) 4.7 × 10−5 (3.3 × 10−3)
PC aa C34:4 0.11 (0.02) 1.5 × 10−10 (1.3 × 10−9) 0.13 (0.02) 1.9 × 10−8 (1.3 × 10−6)
PC aa C36:4 0.14 (0.02) <1.0 × 10−12 (<1.0 × 10−12) 0.15 (0.02) <1.0 × 10−12 (<1.0 × 10−12)
PC aa C36:5 0.16 (0.02) <1.0 × 10−12 (<1.0 × 10−12) 0.17 (0.02) <1.0 × 10−12 (<1.0 × 10−12)
PC aa C36:6 0.11 (0.02) 2.1 × 10−10 (1.6 × 10−9) 0.10 (0.02) 6.2 × 10−6 (4.4 × 10−4)
PC aa C38:5 0.09 (0.02) 1.9 × 10−7 (1.1 × 10−6) 0.11 (0.02) 6.3 × 10−6 (4.6 × 10−4)
PC aa C38:6 0.12 (0.02) <1.0 × 10−12 (<1.0 × 10−12) 0.09 (0.02) 7.8 × 10−5 (5.6 × 10−3)
PC ae C30:2 −0.05 (0.01) 5.0 × 10−5 (1.7 × 10−4) −0.07 (0.02) 4.4 × 10−5 (3.1 × 10−3)
PC ae C32:1 0.06 (0.02) 1.8 × 10−5 (6.8 × 10−5) 0.08 (0.02) 2.1 × 10−4 (1.5 × 10−2)
PC ae C36:0 0.16 (0.02) <1.0 × 10−12 (<1.0 × 10−12) 0.15 (0.02) 9.0 × 10−11 (6.5 × 10−9)
PC ae C36:2 −0.11 (0.02) <1.0 × 10−12 (<1.0 × 10−12) −0.14 (0.02) 1.3 × 10−9 (9.5 × 10−8)
PC ae C36:5 0.10 (0.02) 1.0 × 10−11 (1.0 × 10−10) 0.13 (0.02) 5.3 × 10−9 (3.8 × 10−7)
PC ae C38:3 −0.09 (0.02) 5.9 × 10−9 (3.8 × 10−8) −0.09 (0.02) 8.2 × 10−5 (5.9 × 10−3)
PC ae C40:6 −0.06 (0.02) 2.8 × 10−4 (7.3 × 10−4) −0.08 (0.02) 5.4 × 10−4 (3.9 × 10−2)
SM C20:2 −0.06 (0.01) 1.4 × 10−6 (6.8 × 10−6) −0.08 (0.02) 4.8 × 10−7 (3.5 × 10−5)
SM C24:0 0.04 (0.01) 1.3 × 10−6 (6.3 × 10−6) 0.05 (0.01) 2.7 × 10−5 (1.9 × 10−3)
SM C24:1 0.03 (0.01) 2.8 × 10−5 (1.0 × 10−4) 0.04 (0.01) 5.2 × 10−4 (3.8 × 10−3)
SM(OH) C14:1 −0.06 (0.01) 3.9 × 10−7 (2.1 × 10−6) −0.08 (0.02) 2.4 × 10−6 (1.7 × 10−4)
SM(OH) C16:1 −0.05 (0.01) 2.6 × 10−6 (1.1 × 10−5) −0.08 (0.02) 2.1 × 10−7 (1.5 × 10−5)
SM(OH) C22:2 −0.05 (0.01) 1.3 × 10−7 (8.3 × 10−7) −0.05 (0.01) 2.3 × 10−5 (1.6 × 10−3)
Abbreviations: β, unstandardized regression coefficient derived from multivariable linear models; Bonf.-adj.
p-value, Bonferroni-adjusted p-value; SE, standard error. For an explanation of abbreviated metabolite names,
see Table S1. a Analyzed with multivariable linear regression analyses analyzing associations of alcohol consumption
(ln-transformed alcohol intake + 1) as main independent variable and as dependent variables the residuals obtained
from linear mixed models with Z-standardized ln-transformed metabolite concentrations as dependent variables,
sex as independent variable, and random intercepts for analytical batches nested within studies. Adjusted for: sex;
age (y; continuous), body mass index (kg/m2; continuous), self-reported physical activity levels (Cambridge physical
activity index [23]: inactive, moderately inactive, moderately active, active, unknown), fasting status (≥6 h, 3–5.9 h,
<3 h, unknown), meat intake (g/day; continuous), fish intake (g/day; continuous), energy intake (kcal/day;
continuous), country, and smoking status (current, former, never, unknown). b The discovery and replication
set were taken as random samples without replacement of 66.7% and 33.3% of the total dataset, respectively.
c The analysis in the discovery set was adjusted for multiple testing using the false discovery rate (FDR) method.
d The analysis in the replication set was adjusted for multiple testing using Bonferroni correction.
3.4. Heterogeneity by Sex and Smoking Status
Significant interactions by sex and smoking status were found for 11 and three metabolites,
respectively, in the discovery set after FDR adjustment, as shown in Tables S5 and S6.
In the analysis stratified by sex, a total of 68 and seven metabolites were found to be statistically
significant after FDR-adjustment in men (n = 1378) and women (n = 378), respectively (Table S5).
An analysis of the overlap (Figure S3) indicated that the majority of metabolites identified in sex-specific
models had also been found in the main analysis, consistently in men (63 out of 68) and women
(seven out of seven).
Analysis in never smokers only revealed that 31 metabolites were significantly related to alcohol
intake, of which 29 metabolites were previously identified in the main analysis, mostly with the same
directions and overall similar magnitude of associations (Table S6).
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3.5. Sensitivity Analyses
Visual inspection of penalized spline regression models of metabolite concentrations against
ln-transformed alcohol did not provide strong evidence for non-linear associations of alcohol intake
with metabolite concentrations (Figure S4).
In addition, the analysis comparing heavy (>40 g/day of alcohol) vs. light (0.1–4.9 g/day) drinking
gave similar results as the main analysis (Table S7). The majority of significant metabolites (86.2%)
had also been identified in the main analysis (Figure S5). Four metabolites were significantly related
to extreme alcohol consumption but not to alcohol as continuous variable, i.e., the amino acid serine,
lysoPC a C20:4, PC aa C40:4, and PC ae C40:6.
The regression coefficients obtained from analysis stratified by sub-study, for the 34 metabolites
detected as significant in the replication dataset, indicated a satisfactory level of consistency of estimates
across sub-studies (Figure S6).
4. Discussion
In this study, which is one of the largest to explore the associations between circulating
metabolites and alcohol consumption, alcohol intake was related to several phospho- and sphingolipids.
In particular, we observed associations with circulating concentrations of four lysoPCs, 13 diacyl PCs,
seven acyl-alkyl PCs, and six SMs. In addition, alcohol was related to three acylcarnitines and the
amino acid citrulline.
Of the 38 replicated metabolites associated with alcohol in our study, 10 metabolites were
similarly linked to alcohol in two previous studies in German populations, namely the KORA study,
conducted in 1144 men and 946 women [9], and the CARLA study, a combined analysis of 534 men
and 496 women [10] (Figure 3). Another 12 of these 38 metabolites were observed in the KORA
study [9] only. The metabolites overlapping with these studies included lysoPC a C16:1 and lysoPC
a C17:0, and several diacyl PCs, acyl-alkyl PCs, and SMs. Two of the overlapping diacyl PCs have
also been associated with wine intake in a study including over 3500 female twins from the United
Kingdom, i.e., PC aa C32:1 and PC aa C36:5 [11].
These findings suggest potential biological disrupting conditions related to alcohol
consumption [9,10]. Lower SM concentrations in individuals with higher alcohol consumption
may have resulted from alcohol-induced activation of the enzyme acid sphingomyelinase (ASM),
which leads to increased catabolism of SMs into ceramide and PCs [36,37]. This could lead to
hepatotoxicity [38,39]. Low acyl–alkyl PCs and high diacyl PCs may reflect less lipid remodeling in
membranes resulting in inflammation [40], which may, in turn, be associated with alcohol-related
pathologies [41]. High lysoPCs may be the result of alcohol-induced stimulation of several metabolic
pathways [9,10]. LysoPCs have been associated with increased levels of oxidative stress [10], that has
been related to alcohol-induced liver diseases [42]. The association of alcohol intake with blood
concentrations of lysoPC a C17:0 may reflect negative confounding by dairy consumption among
people with high alcohol intake [9,10], as the fatty acid C17:0 is specifically found in milk fat and cannot
be synthesized in the human body [43]. However, a significant inverse association was still observed
when we additionally adjusted the analysis of alcohol with lysoPC a C17:0 for dairy consumption
(results not shown).
We also observed associations with metabolites that had not been identified before,
including positive associations with three acylcarnitines and inverse associations with the amino
acids citrulline and serine (the latter only with heavy vs. light drinking). Acylcarnitines are related
to mitochondrial oxidation of fatty acids and are biomarkers of mitochondrial dysfunction [44].
Higher plasma concentrations of acylcarnitines have been observed in patients with alcohol-induced
cirrhosis in comparison to healthy controls [45,46]. This dysregulation of carnitine metabolism may be
caused by an increased carnitine biosynthesis induced by increased muscle protein turnover in cirrhotic
patients [45]. Citrulline is a key intermediate in the urea cycle [47], while serine is a proteinogenic amino
acid and a precursor of other important metabolites including sphingolipids and nucleotides [48].
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Lower concentrations of these amino acids observed in participants with higher alcohol intake may
reflect a dysregulation of these metabolic pathways. Previous population-based studies did not find
associations of alcohol intake with serine, whilst citrulline was not measured in these studies [9–11].
Further research will be necessary to replicate our findings, and investigate whether these metabolites
relate to alcohol-related diseases.
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Figure 3. Venn diagram showing overlap in metabolites identified as significantly associated with
alcohol intake after discovery and replication analysis in the current study (EPIC) and those identified
by two other previous German population-based studies that were described by Jaremek et al. [9]
(KORA study; sex-stratified analysis in 1144 men and 946 women) and Lacruz et al. [10] (CARLA study;
combined analysis in 534 men and 496 women), that applied the previous version of the assay
used in the current analysis (i.e., BIOCRATES AbsoluteIDQTM p150 kit; p180 kit was used in the
current analysis). An upwards arrow indicates a positive association (i.e., higher alcohol intake
associated ith higher blood concentrations of the etabolite), while a downwards arrow indicates
a negative association (i.e., higher alcohol intake associated ith lo er etabolite concentrations).
Footnote: The total number of metabolites (n = 125) is more than those included in the current analysis
(n = 123) as two metab lites measured in the KORA and/or CARLA study were not included in the
current analysis (acylcarnitine C16:1 and acylc rnitine C16:2; see Table S1). For an explanation f
abbreviated metabolite names, see Table S1.
Similarly to the CARLA study [10], we did not observe strong heterogeneity of alcohol-metabolite
associations by sex as significant interactions were found for 11 metabolites only. In sex-specific
analyses in the KORA study, only a subset of the metabolites that were significantly related to alcohol
intake in men were also observed in women [9], possibly reflecting a lower sample size and lower
alcohol intake in women compared to men. We did not find strong evidence of heterogeneity in
associations between alcohol consumption and metabolite concentrations by smoking status, with three
statistically significant interactions only. Several metabolites identified in the overall analysis were not
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related to alcohol in never smokers, which may suggest residual confounding, or may be due to the
lower sample size among never smokers.
An important strength of our study is the large sample size including controls from four nested
case-control studies within EPIC, encompassing wide variability in alcohol intake and metabolite
concentrations. The comprehensive evaluation of the contribution of lifestyle and laboratory variables
to overall metabolite variability through the PC-PR2 analysis enabled proper adjustment in our
evaluation. An important element of our study was the use of discovery and replication sets that
increased the reliability of our findings [49]. The metabolomics analyses were undertaken in one
laboratory, thus avoiding inter-laboratory variability [26]. Overall, the consistency of our results with
findings in previous studies using the same assay [9,10], and the associations with metabolites involved
in lipid pathways in observational studies with different assay methods [50–52] suggests that our
findings are robust.
Among the limitations of our study, alcohol intake at recruitment was self-reported, which may
be prone to misreporting [53], although alcohol measurements in EPIC were validated against multiple
24-h recalls with Spearman correlation of 0.79 [54]. Our analysis was cross-sectional, limiting the
possibility of assessing causality. Results of the PC-PR2 analysis showed that the factor ‘sub-study’
explained a relatively large percentage of variability in metabolite concentrations, likely due to
analytical differences, e.g., time of acquirement and mass spectrometer used, and population
characteristics. Proper adjustment for sub-study was carried out in our analysis using the residual
method. Furthermore, results of the sensitivity analysis stratified by sub-study indicated a satisfactory
level of consistency across sub-studies. In the hepatobiliary cancer case-control study serum samples
were analyzed, while in other studies citrate plasma was used. Although absolute concentrations of
metabolites in the two matrices may differ, high correlation between serum and plasma measurements
have been observed for the majority of metabolites in the BIOCRATES assay with a mean Pearson
correlation of 0.81 [55], and a good reliability for most metabolites in both serum and plasma has
been found [55,56]. Furthermore, there were no differences in results when we excluded hepatobiliary
cancer controls. Our samples included both fasting and non-fasting samples, but the PC-PR2 analysis
conducted in our study showed limited impact of fasting on variability of metabolite concentrations
and we adjusted for fasting status in our analysis. Furthermore, it has been found within the EPIC
study that the majority of metabolites of the BIOCRATES kit were reliably measured in fasting and
non-fasting samples, although a lower stability for certain acylcarnitines, PCs, and SMs was found for
non-fasting samples [25].
5. Conclusions
In conclusion, findings from this large European study confirm that alcohol intake was associated
with circulating concentrations of several phospholipids and sphingolipids, and provide novel
evidence of a relationship with concentrations of acylcarnitines and specific amino acids. More research
will be necessary to replicate these findings in other study populations. The availability of longitudinal
data would clarify whether alcohol intake could modify specific metabolic responses within the same
individuals over time.
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Figure S1: Flow chart of participant inclusion into the European Prospective Investigation into Cancer and
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discovery dataset, stratified by sub-study, i.e., colorectal cancer (CRC), kidney cancer (KC), hepatobiliary cancer
(HC), and prostate cancer (PC) case-control study. Table S1: Information on measurements of metabolites included
in the BIOCRATES AbsoluteIDQ™ p180 kit in the total dataset and in each sub-study, and whether the metabolite
was included for the current analysis, Table S2: Participant characteristics by sub-study (nested case-control
study the controls were derived from) and in the total dataset, Table S3: Summary statistics of untransformed
concentrations (µM) of metabolites included in the current analysis (n = 123), Table S4: Results of discovery
and replication analysis on associations of alcohol intake with concentrations of metabolites included in the
current analysis (n = 123), Table S5: Comparison of results of sex-stratified discovery analysis on associations of
alcohol intake with concentrations of included metabolites (n = 123) with results obtained in the total discovery
set and results of statistical interaction analysis for sex, Table S6: Comparison of results of discovery analysis on
associations of alcohol intake with concentrations of included metabolites (n = 123) in never smokers only with
results obtained in the total discovery set and results of statistical interaction analysis for smoking status, Table S7:
Results of discovery and replication analysis on associations of categories of alcohol intake (heavy vs. light) with
concentrations of metabolites included in the current analysis (n = 123).
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